Paratek shares shoot up on a pos­i­tive PhI­II and a slow-mo shot at FDA/EMA OK for its an­tibi­ot­ic

Shares of Paratek shot up 30% $PRTK in af­ter-mar­ket trad­ing on Mon­day as in­vestors re­act­ed to the Boston biotech’s procla­ma­tion of a clean sweep for its piv­otal test of its new an­tibi­ot­ic omada­cy­cline. Ex­ecs said that their broad spec­trum an­tibi­ot­ic hit its pri­ma­ry and sec­ondary end­points for the FDA as well as the co-pri­maries need­ed for the EMA in their sec­ond pos­i­tive late-stage tri­al.

Re­searchers went look­ing for ev­i­dence that omada­cy­cline matched up with mox­i­floxacin in the treat­ment of pa­tients with com­mu­ni­ty-ac­quired bac­te­r­i­al pneu­mo­nia (CABP). And that’s what they got, with ear­ly clin­i­cal re­sponse rates scor­ing 81.1 % and 82.7% in new and old an­tibi­otics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER